Nephros (NEPH)
(Delayed Data from NSDQ)
$2.29 USD
+0.14 (6.51%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $2.30 +0.01 (0.44%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NEPH 2.29 +0.14(6.51%)
Will NEPH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NEPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NEPH
Nephros Inc. (NEPH) Reports Q3 Loss, Misses Revenue Estimates
Lantheus Holdings (LNTH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
NEPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Nephros Inc. (NEPH) Report Negative Earnings Next Week? What You Should Know
Nephros Inc. (NEPH) Reports Q2 Loss, Tops Revenue Estimates
Other News for NEPH
GEE Group And 2 Other Stocks Under $3 Insiders Are Buying
Insider Buying: President and CEO Banks Robert R. Jr. Acquires 50,000 Shares of Nephros Inc (NEPH)
Novavax, Capricor Therapeutics, Arcutis Biotherapeutics among healthcare movers
Nephros: Buy Rating Affirmed Amid Solid Performance and Growth Prospects
Nephros files $50M mixed securities shelf